BiotechTube

Switch to B/F/TAF + Continue current regimen

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

HIV-1-infection

Conditions

HIV-1-infection

Trial Timeline

Feb 1, 2022 → Mar 18, 2024

NCT ID
NCT05243602

About Switch to B/F/TAF + Continue current regimen

Switch to B/F/TAF + Continue current regimen is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05243602. Target conditions include HIV-1-infection.

What happened to similar drugs?

11 of 18 similar drugs in HIV-1-infection were approved

Approved (11) Terminated (3) Active (6)
✅B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
✅B/F/TAFGilead SciencesApproved
✅Genvoya + Epclusa + BiktarvyGilead SciencesApproved
✅F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)Gilead SciencesApproved
✅Maraviroc + TruvadaGilead SciencesApproved
✅B/F/TAF + TDF/3TC/EFVGilead SciencesApproved
✅Bictegravir/emtricitabine/tenofovir alafenamideGilead SciencesApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05243602ApprovedCompleted

Competing Products

20 competing products in HIV-1-infection

See all competitors
ProductCompanyStageHype Score
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
18F-RaltegravirMerckPhase 1
36
ISL/LEN + Antiretroviral CombinationsMerckPhase 3
44
Delstrigo + KOCITAFMerckPhase 3
44
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LENMerckPhase 3
44
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
35
GS-3242 + BVY + Standard of CareGilead SciencesPhase 1
36
B/F/TAFGilead SciencesApproved
43
Genvoya + Epclusa + BiktarvyGilead SciencesApproved
39
GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDCGilead SciencesPhase 2/3
42
Dapivirine + TruvadaGilead SciencesPhase 2
27
Bictegravir/emtricitabine/tenofovir alafenamideGilead SciencesPre-clinical
22
GS-9131 + BIC + TAF + ARV regimen + DRV + RTVGilead SciencesPhase 2
27
Bavtavirine + B/F/TAF + Standard of Care (Substudy 01) + GS-1720 + Standard of Care (Substudy 02) + GS-6212 + Standard of Care (Substudy 03)Gilead SciencesPhase 1
29
TruvadaGilead SciencesPhase 2
42
B/F/TAFGilead SciencesPhase 1
29
B/F/TAF + F/TAF + DTG + DTG Placebo + F/TAF Placebo + B/F/TAF PlaceboGilead SciencesPhase 3
40
GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDCGilead SciencesPhase 2/3
42
Vesatolimod + VRC07523LS + CAP256V2LSGilead SciencesPhase 2
35
F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)Gilead SciencesApproved
50